Ferric carboxymaltose for iron-deficiency anemia secondary to gastrointestinal bleeding: a systematic review and meta-analysis.
Refinessuggested applicable standard· American Gastroenterological Association, "AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review," 2024
Decision at stakechoice of IV iron formulation for patients with inadequate response to optimized oral iron
… Judge response objectively: in an adherent anemic patient, hemoglobin should increase by about 1 g/dL within 2 weeks and ferritin should show improvement within about 1 month, expected responses that serve to confirm adherence and adequate absorption during the oral trial, not fixed cutoffs whose miss by itself mandates IV iron; a shortfall should prompt reassessment of adherence and absorption, and escalation to IV iron rests on an inadequate response to an adequate trial of oral iron. …
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standard
Per the AGA 2024 management update (Best Practice Advice statements): Start oral iron; no single oral formulation is superior and ferrous sulfate is preferred as the least expensive (BPA1). Dose oral iron once daily at most, with every-other-day dosing an accepted alternative that may be better tolerated at similar or equal absorption (BPA2). Add vitamin C to improve absorption (BPA3). Judge response objectively: in an adherent anemic patient, hemoglobin should increase by about 1 g/dL within 2 weeks and ferritin should show improvement within about 1 month, expected responses that serve to confirm adherence and adequate absorption during the oral trial, not fixed cutoffs whose miss by itself mandates IV iron; a shortfall should prompt reassessment of adherence and absorption, and escalation to IV iron rests on an inadequate response to an adequate trial of oral iron. Use IV iron if the patient cannot tolerate oral iron, if ferritin/blood counts do not improve with a trial of oral iron, or in a condition where oral iron is unlikely to be absorbed, the update names active inflammatory bowel disease and the post-bariatric state (particularly procedures disrupting duodenal absorption, in a patient with no identifiable source of chronic GI blood loss) (BPA4, BPA7). Prefer IV formulations that replace the deficit in 1-2 infusions over those needing more than 2; all IV formulations carry similar risk and true anaphylaxis is very rare (BPA5, BPA6). Condition-specific qualifiers the update keeps separate: in IBD, first determine whether the anemia reflects inadequate intake/absorption versus GI blood loss and treat active inflammation to improve absorption/reduce loss; in celiac disease, ensure gluten-free-diet adherence to restore absorption rather than defaulting straight to IV; for gastric antral vascular ectasia with an inadequate response to iron replacement, use endoscopic therapy (band ligation or argon plasma coagulation) rather than treating it as an absorption problem. The update also suggests that in uncomplicated asymptomatic patients with negative bidirectional endoscopy, a trial of iron is preferred over routine video capsule endoscopy.